Aptinyx Inc logo Cantor Fitzgerald restated their buy rating on shares of Aptinyx (NASDAQ:APTX) in a research report report published on Wednesday, January 16th. The brokerage currently has a $40.00 price objective on the stock.
“We reiterate our Overweight rating and 12-month PT of $40 on APTX. With an initial focus on large indications within chronic pain, there are multiple other nervous system disorder oppys for the company’s candidates with better safety/tolerability profile relative to historical NMDAr-based treatments like ketamine. Data from pre-clinical models looks promising and important POC trial data will emerge in pain indications The Disclosure Section may be found on pages 4 – 5.in 1H19, which we believe has a above-average PoS and will significantly move the stock.”,” the firm’s analyst wrote.
Aptinyx stock traded up $0.10 during midday trading on Wednesday, reaching $5.50. 91,534 shares of the stock were exchanged, compared to its average volume of 682,896. Aptinyx has a 52 week low of $4.70 and a 52 week high of $32.25.
Aptinyx (NASDAQ:APTX) last posted its earnings results on Tuesday, November 13th. The company reported ($0.43) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($1.01) by $0.58. The firm had revenue of $0.94 million for the quarter, compared to the consensus estimate of $1.10 million. Research analysts expect that Aptinyx will post -2.55 EPS for the current year.
In other Aptinyx news, CFO Ashish Khanna acquired 10,000 shares of the business’s stock in a transaction dated Friday, January 18th. The stock was bought at an average price of $5.45 per share, with a total value of $54,500.00. The transaction was disclosed in a filing with the SEC, which is accessible through this link . Also, Director Robert J. Hombach acquired 25,000 shares of the business’s stock in a transaction dated Friday, January 25th. The stock was acquired at an average cost of $5.53 per share, with a total value of $138,250.00. The disclosure for this purchase can be found here . In the last three months, insiders acquired 36,050 shares of company stock valued at $198,284.
Several institutional investors have recently made changes to their positions in APTX. Legal & General Group Plc purchased a new stake in Aptinyx during the 3rd quarter valued at $58,000. Strs Ohio purchased a new stake in Aptinyx during the 3rd quarter valued at $110,000. Wells Fargo & Company MN purchased a new stake in Aptinyx during the 3rd quarter valued at $185,000. New York State Common Retirement Fund purchased a new stake in Aptinyx during the 4th quarter valued at $200,000. Finally, Virtus ETF Advisers LLC purchased a new stake in Aptinyx during the 4th quarter valued at $230,000. 64.76% of the stock is owned by institutional investors.
Aptinyx Company Profile
Aptinyx Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. It is developing NYX-2925 that is in Phase II clinical trial for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II exploratory clinical trial for fibromyalgia; and NYX-783, an NMDAr receptor that is in Phase I clinical trial for the treatment of post-traumatic stress disorder.
Recommended Story: How is the LIBOR rate calculated? Analyst Recommendations for Aptinyx (NASDAQ:APTX) Receive News & Ratings for Aptinyx Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Aptinyx and related companies with MarketBeat.com’s FREE daily email newsletter .
Click here to view original web page at Aptinyx (NASDAQ:APTX) Rating Reiterated by Cantor Fitzgerald